(Zhang et al., 2009a) have developed alpha-bromophosphonate analogues of LPA that inhibitATX activity and also are antagonists of LPA1,2,3,4,5 GPCR and showed that these dual-action compounds not only reduce breast cancermetastasis but also inhibit tumour growth.